This is a Phase 2a, single-arm, open-label, exploratory study assessing the efficacy and safety of LAM-001 as an add-on therapy for the treatment of WHO functional class III subjects with WSPH Group-1 or Group-3 pulmonary hypertension.~Approximately fifteen participants will receive standard of care plus LAM-001 (inhaled sirolimus) 100 mcg by oral inhalation once daily for the first 24 weeks of the study (Core Study).~Participants who complete the first 24 weeks on treatment and appear to have a favorable benefit-risk profile will be eligible to continue receiving LAM-001 (inhaled sirolimus) for the remainder of the study (Extension Period) up of 12 months.~All participants will complete evaluations during a Follow-Up Period of 4 weeks.
This is a clinical trial to assess the efficacy and safety of LAM-001 as an add-on therapy for the treatment pulmonary hypertension.